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Accurate and reliable diagnostic tools are an essential requirement for neglected tropical diseases (NTDs) pro-
grammes. However, the NTD community has historically underinvested in the development and improvement of
diagnostic tools, potentially undermining the successes achieved over the last 2 decades. Recognizing this, the
WHO, in its newly released draft roadmap for NTD 2021–2030, has identified diagnostics as one of four priority
areas requiring concerted action to reach the 2030 targets. As a result, WHO established a Diagnostics Technical
Advisory Group (DTAG) to serve as the collaborative mechanism to drive progress in this area. Here, the purpose
and role of the DTAG are described in the context of the challenges facing NTD programmes.
Keywords: diagnostics, neglected tropical diseases, target product profiles, WHO
Introduction
The 2012 WHO neglected tropical diseases (NTDs) roadmap
and subsequent London declaration on NTDs galvanised inter-
national support for the control and elimination of NTDs by
2020.1 Renewed and expanded drug donations and financial
commitments created a favourable environment for the scaling
up of control and elimination programmes across all NTD-
endemic geographies. Today, the scope of global programmes
targeting NTDs is unprecedented, reaching more than one billion
people annually and an increasing number of countries are
achieving elimination goals.2 Despite enormous successes, NTD
programmes have not yet met their original and ambitious 2020
targets, necessitating the development of a new NTD roadmap
for 2021–2030.
The 2021–2030 roadmap is meant to serve as a guiding doc-
ument to facilitate alignment across the global community of
NTD partners by defining global targets to guide the delivery
of programmes across the 20 WHO-targeted NTDs.3 It is also
intended to serve as a policy and advocacy document, draw-
ing attention to the key challenges facing NTD programmes
and encouraging continued commitment from the global com-
munity of partners. Among the priority areas identified in the
roadmap, the following four are considered to have the most
critical gaps impeding progress towards the 2030 targets across
multiple NTDs:
 Diagnostics.
 Monitoring and evaluation (M&E).
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 Access and logistics.
 Advocacy and funding.
Accurate, reliable and affordable diagnostic tools are an
essential requirement for NTD programmes. They support
individual-level treatment choices, inform population-level deci-
sions on changing treatment frequency or stopping mass treat-
ment, enable disease surveillance and allow for confidence in
validating or verifying elimination or certifying eradication. Sim-
ply put, diagnostic tools are the drivers of M&E and are critical to
documenting impact. Although classical clinical and microscopic
techniques are often adequate for mapping disease distribution
and for monitoring the progress of most NTD interventions, the
need for improved diagnostics comes into much sharper focus
as infection prevalence declines and elimination or eradication
becomes a possibility.4,5 The NTD community has traditionally
underinvested in the development and improvement of diag-
nostic tools, potentially undermining the success that has been
achieved.
As an indication of the magnitude of the need for new diag-
nostic tools, in the WHO 2030 Roadmap, 13 disease commu-
nities listed diagnostics among their top three critical actions
to reach the 2030 targets and 18 diseases indicated that diag-
nostics require critical action to reach the 2030 targets.3 Where
existing diagnostics are in theory sufficient for programmatic
needs, the availability of tests at the correct levels of the
health system may be a challenge. Both new tests and test
formats are now needed to achieve the 2021–2030 roadmap
targets.
Identifying diagnostics as a priority area provides formal
acknowledgment of the critical role these tools play in monitor-
ing and evaluating NTD programmes and reinforces the necessity
for the NTD community to allocate resources for diagnostic tools
to achieve the 2030 targets.
Development of the Diagnostic Technical
Advisory Group
In 2009, the WHO Department of Control of Neglected Trop-
ical Diseases established an M&E working group to engage
researchers and programme implementers in the development
of standardised tools to strengthen M&E frameworks across all
NTDs. Reports from the field indicated that multiple NTD pro-
grammes were facing challenges with diagnostic tools that were
lacking in sensitivity and specificity, and which were unreliable or
inaccessible. As a result, the M&E working group recommended
that a dedicated diagnostics group be developed, a recommen-
dation that was endorsed by the Strategic Technical Advisory
Group.6 The Diagnostics Technical Advisory Group (DTAG) was
then established in anticipation of the 2030 roadmap and to
serve as the WHO’s mechanism for collaborative development of
new diagnostic tools.7
The DTAG was charged with responsibility to:
 Review and prioritise diagnostics needs for NTD programmes.
 Define the use cases (i.e. the programmatic context in which
the test is used) and target product profiles (TPPs) for the nec-
essary diagnostic tools.
 Link with key partners to support test development and valida-
tion.
 Provide the WHO with guidance on the utility of new tools to
support the control and elimination of NTDs.
DTAG members were selected to represent a broad range
of expertise in test development, M&E and programme imple-
mentation, as well as disease-specific expertise. Recognising that
such a small membership would struggle to provide the in-depth
expertise required to address all 20 NTDs, development of time-
limited subgroups was recommended to provide more specific
expertise.
The development of the DTAG provides formal WHO recogni-
tion of the extent of the diagnostics challenge in achieving the
2030 targets and represents the first large-scale, coordinated
strategy to address it. It will provide an essential connection
between theWHO, the donor community and product developers
to ensure that the needs of the programmes will be met.
Defining the agenda
At the inaugural meeting of the DTAG in October 2019, it was
noted that the vast majority of NTD programmes rely upon diag-
nostic tools to facilitate interventions at the individual level or
public health actions at the population level. Consultations across
the NTD community provided a landscape analysis that guided
discussions at the meeting. Limited resources require prioritisa-
tion of themost urgent needs, bearing in mind that all diagnostic
needs across all 20 NTDs will have to be addressed over time.
Prioritisation of needs is not a straightforward task. The exer-
cise required a defined set of criteria upon which to rank needs
and their urgency. To provide a transparent basis for establish-
ing initial priorities, DTAG members employed an algorithm that
considered the current state of the programme targeting a spe-
cific NTD, and whether a new diagnostic tool is needed to inform
decision-making for existing programmes or to achieve 2030 tar-
gets. If a newdiagnostic tool is necessary, either to provide essen-
tial support for an ongoing programme or to meet 2030 targets,
then the priority is considered to be high. NTDs that lack a broadly
accepted public health strategy andwhich are not addressed cur-
rently by a global programmewere acknowledged to have impor-
tant needs for investment in research, but were not considered
to represent critical diagnostic priorities at this stage. Prioritisa-
tion exercises will be revisited on an annual basis to keep desig-
nated priorities aligned with evolving programme strategies and
needs.
For NTDs for which preventive chemotherapy forms an impor-
tant part of the public health response, the need for better surveil-
lance tools is cross-cutting. For lymphatic filariasis, the introduc-
tion of a triple-drug therapy comprising ivermectin, diethylcar-
bamazine and albendazole may reduce the number of rounds
of mass drug administration required, thus reducing the utility
of current antigen tests for stopping decisions based on trans-
mission assessment surveys. For onchocerciasis, the performance
of existing tests is inadequate in low prevalence settings, and
for soil-transmitted helminths and schistosomiasis, the depen-
dence on the collection of stool and urine samples presents
both logistical and laboratory challenges. For diseaseswhere case
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management is critical, improved point-of-care rapid diagnos-
tic tests and high quality molecular tests are urgently needed.
The new focus on integrated management of skin diseases, as
outlined in the 2030 roadmap, would be strengthened by the
deployment of multiplex tests that support differential diagnosis;
these tests will need to address the additional challenge of com-
mon and standardised sample processing and target concentra-
tion/enrichment process. Specific needs for high priority use cases
(defined using the approach described above) are summarised in
Table 1.
New scientific opportunities
Although the diagnostic needs for NTD programmes are exten-
sive, there is reason to be optimistic about the prospects of
development of new tools to address programme requirements.
The past 20 y have seen an explosion in the development of
new molecular biology methods, including rapid and low-cost
genome sequencing and new approaches to analyse proteomes
and secretomes. This technology has been applied to several
NTDs, leading to identification of potential new biomarkers and,
in some cases, tests that are already being evaluated in the lab-
oratory and in the field. For example, several approaches are
being employed to identify targets for onchocerciasis serologi-
cal assays to support programmatic decision-making.8–11 These
efforts should be expanded to include other NTDs. In particular,
promising new epitope screening technologiesmay help to accel-
erate the identification of novel targets and permutations of tar-
gets for serological assays.12
In principle, the development of nucleic acid tests for diag-
nosis should be ‘low hanging fruits’; however, the lack of labo-
ratory capacity to run molecular tests and the lack of standard-
isation of test formats have prevented test deployment on the
scale needed by most programmes. These challenges must be
addressed by development of either laboratory capacity, poten-
tially through leveraging laboratory capacity for other diseases
such as HIV and TB, or development of tests that do not require
laboratory infrastructure for their performance. Test standardisa-
tion is necessary to ensure that treatment and programme deci-
sions are based on consistent criteria.
Independent of the test format, once candidate assays are
identified, more vigorous efforts to coordinate assay validation
processes are needed to improve the rate at which new tests can
be introduced into programmes. Certified referencematerials will
also be needed to evaluate test performance at individual labo-
ratories once a new test has been rolled out. The COVID-19 pan-
demic has illustrated the relative speed at which new diagnostic
tools can be developed when resources are abundant and col-
laborations are intensified. In the absence of new resources, the
NTD community will have to create incentives for test develop-
ers by defining clear processes for regulatory approval and adop-
tion of tests by programmes. In addition, advance purchase com-
mitments and novel financing strategies should be considered to
reduce the market risk for test manufacturers. As a more posi-
tive outcome of the pandemic, testing capacity at country level
is expanding dramatically. This will create new opportunities to
introduce molecular testing in settings where this capacity has
been limited.
Moving the agenda forward
Reaching the end game presents new challenges for NTD pro-
grammes as infection prevalence declines and incident cases
become increasingly rare. Surveillance is a requirement to sup-
port claims that a disease has been eliminated or eradicated,
but disease-specific surveillance strategies become harder to jus-
tify when resources are limited and active interventions have
stopped. Multi-disease surveillance makes sense, in principle, but
has been challenging to achieve in practice because of differ-
ing disease geographies, target populations, test formats and the
traditionally vertical nature of some programmes. Although inte-
grated serosurveillance is finding increased use as a research tool,
the assay platforms typically require laboratory infrastructure
and are not well standardised among laboratories.13–15 Innova-
tive technologies that will support low-cost and flexible multi-
disease surveillance are needed.Where programmedecisions are
made at the population level, surveys and survey design become
an integral part of diagnosis; therefore, it is critical to capitalise on
the use of new geostatistical tools that can lead tomore efficient
survey designs.16
As noted above, an essential role for theDTAG is to help provide
clarity, both to test developers and donors on the critical needs of
NTD programmes. Disease-specific subgroups have been created
to develop detailed descriptions of the programmatic use case
to provide useful context and guidance for scientists and prod-
uct developers working to support the 2021–2030 NTD roadmap,
with a particular emphasis on the generation of detailed TPPs to
guide test development. Once drafted, TPPs will be posted on the
WHO’s Global Observatory on Health Research and Development
for a 28-d period of public consultation prior to finalisation.
Cross-cutting groups are under development to address a
range of issues common across NTDs, including:
 Surveillance platforms.
 Clinical diagnosis, imaging and microscopy.
 Manufacturing and regulatory pathways.
 Resource mobilisation.
The surveillance subgroup will focus on survey design, assay
technology and tool adaptation for the surveillance setting. The
clinical diagnosis, imaging and microscopy group will address
topics such as improved training methodologies and materials,
the criteria for evaluating diagnostic image analysis andmachine
learning as well as access issues limiting the availability of image
libraries. The manufacturing and regulatory pathways will be
charged with developing innovative strategies for overcoming
barriers to test availability due to the absence of a large global
market (i.e. extendeddevelopment timelines andhigh unit costs).
This subgroup will serve as the crucial link between the disease-
specific subgroups and product developers, both those new and
familiar to the NTD field, to ensure the translation of TPPs into
real diagnostic tools capable of serving the needs of the pro-
grammes. The group will also work with the WHO to understand
and fulfil regulatory requirements as new tools progress through
the development pipeline. The resource mobilisation subgroup
will work to improve coordination among existing donors, engage
new donors and strengthen links between the WHO and the NTD
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diagnostics community. New cross-cutting subgroups may be
established as the needs of the DTAG evolve.
As the work of the initial subgroups has progressed, additional
topics have emerged with implications for multiple diseases. The
operational challenge of test validation when trying to achieve
very high sensitivity and specificity requirements has been raised
as a subject for future strategising by test developers. For exam-
ple, to demonstrate a 99.7% diagnostic specificity (discussed
in the context of a hypothetical immunoassay), thousands of
serum samples of sufficient volume would be needed for vali-
dation from across representative geographies, with and without
various important coinfections, especially when confronted with
the realities of laboratory validation such as variances between
test lots. Similarly, several subgroups have raised the challenge
of estimating sensitivity and specificity in the absence of a gold
standard. Without a gold standard, true disease prevalence is
unknown, and therefore sensitivity and specificity cannot be cal-
culated directly. The use of statistical methods, such as latent
class analysis, to overcome the absence of a gold standard, has
been raised as a topic for cross-disease consideration.17–19
Throughout the development from TPPs to new product devel-
opment, the DTAG and its subgroups will rely on well-accepted
field principles to guide activities. The TPP template(s) populated
or reviewed by subgroupswill be based on the REASSURED criteria
for diagnostic use in resource-limited settings: Real-time connec-
tivity, Ease of specimen collection, Affordable, Sensitive, Specific,
User-friendly, Rapid and robust, Equipment-free and environmen-
tally friendly and Delivered to those in need.20 Such principles and
tools will help to ensure that future tools are developed based on
the needs and realities of NTD programmes.
Conclusion
A robust DTAG will create greater awareness of the needs of NTD
programmes and align investments, both financial and scien-
tific, with those needs. Over the long term, the DTAG will play
a more significant role in fostering innovation in the develop-
ment of novel multiplex testing platforms and integrated sur-
veys/screening.
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